


# TENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference PCT 1343/03(VA)	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US03/15404	International filing date (day/month/year) 06 June 2003 (06.06.2003)	Priority date (day/month/year) 07 June 2002 (07.06.2002)	
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 38/16, 38/36 and US Cl.: 514/8; 435/6, 69.1; 530/350			
Applicant U.S. DEPARTMENT OF VETERANS AFFAIRS			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.  
  
☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  
  
 These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 03 December 2003 (03.12.2003)	Date of completion of this report 13 April 2004 (13.04.2004)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 872-9306	Authorized officer Anand Desai <i>A. Roberto for</i> Telephone No. (571) 272-1600

Form PCT/IPEA/409 (cover sheet)(July 1998)

**I. Basis of the report****1. With regard to the elements of the international application:\***

- ☒ the international application as originally filed.
- ☒ the description:  
pages 1-54 as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_.
- ☒ the claims:  
pages 55-59 as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_.
- ☒ the drawings:  
pages 1-6 as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_.
- ☐ the sequence listing part of the description:  
pages NONE as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_.

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:**

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☐ The amendments have resulted in the cancellation of:**

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

**5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.  
PCT/US03/15

## V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. STATEMENT

Novelty (N)	Claims 1-13, 16-19	YES
	Claims 14, 15	NO
Inventive Step (IS)	Claims NONE	YES
	Claims 1-19	NO
Industrial Applicability (IA)	Claims 1-19	YES
	Claims NONE	NO

### 2. CITATIONS AND EXPLANATIONS

Claims 14, and 15 lack novelty under PCT Article 33(2) as being anticipated by Langit et al. (US 2003/0022221 A1). Langit et al. discloses peptide sequences that have been identified as being members related to the lactadherin protein subfamily (see US 2003/0022221 A1, pg. 3, column 1, paragraphs 29, and 30, current application, claims 14, and 15).

Claims 1-13, and 16-19 meet the criteria set out in PCT Article 33(2) because the prior art does not teach all of the elements of these claims in one reference.

Claims 1-19 lack an inventive step under PCT Article 33(3) as being obvious over Langit et al. (US 2003/0022221 A1) in view of Ortel et al. (J. Clin. Invest. Vol. 90, Dec. 1992, pp. 2340-2347). Langit et al. discloses peptide sequences that have been identified as being members related to the lactadherin protein subfamily (see US 2003/0022221 A1, pg. 3, column 1, paragraphs 29, and 30, current application, claims 14, and 15). Ortel et al. found that an inhibitor of Factor V, blocks phosphatidylserine-specific binding of Factor V. Ortel et al. results show that the inhibitor neutralizes the procoagulant activity of Factor Va by interfering with the C2-domain mediated binding to anionic phospholipids, thereby disrupting formation of the prothrombinase complex. Therefore, it would have been obvious to the person having ordinary skill in the art to use the peptides of the lactadherin protein subfamily to compete with the phospholipid binding site of Factor V to bind phosphatidylserine on the cell membrane, and thereby inhibit blood coagulation (current application, claims 1-19).

Claims 1-19 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.